Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

SALT LAKE CITY, July 21, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the full commercial launch of FirstGene^® Multiple Prenatal Screen, the only lab test that runs four prenatal genetic screens simultaneously from a single blood draw as early as eight weeks gestation.^* The FirstGene screen delivers fetal chromosome screening, fetal single-gene screening, patient carrier screening and fetal RhD screening in one integrated report. The screen has greater than 98% analytical sensitivity and greater than 99% analytical specificity.¹